Last week, a study was published in the UK which had some astonishing findings about men and prostate cancer. Two especially stood out:
- One in three men over the age of 45 would put off seeking help for prostate cancer – because they fear every diagnosis is terminal
- Research into 1,200 men over 45, also found nearly two-thirds (62 per cent) believe undergoing treatment for prostate cancer can result in side effects that could impact the quality of life
- Of those who have received treatment, almost half (48 per cent) wish they had known more about how the treatment could have been personalised to them.
- Of the men diagnosed with prostate cancer, more than half (58 per cent) wish they’d known more about the treatment options available.
- More than a third (34 percent) believed that if they had been better informed, they would have chosen a different treatment pathway.
- Despite the prominence of prostate cancer – with one in eight men being diagnosed with the disease in their lifetime – nearly a third (31 per cent) of men aren’t sure what therapies are used
- nearly a fifth (17 per cent) believe treatment for prostate cancer is comprised of chemotherapy alone.
Empowering men to make informed decisions
Decisions require information, confidence and commitment, and the disturbing findings of this report raise the question of how you empower men diagnosed with prostate cancer to make informed decisions. How do you inform, educate and instil the confidence required to make them? How do you make them aware of the need to access information beyond that available in their local NHS trust? Another way of looking at this question is through health literacy. The NHS defines health literacy as follows: Health literacy is about a person’s ability to understand and use information to make decisions about their health. A user with low health literacy will generally struggle to:- read and understand health information
- know how to act on this information
- know which health services to use and when to use them
- look for an independent second opinion on their prostate cancer treatment options